Loading...

Fusen Pharmaceutical Company Limited

1652.HKHKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$0.38
HK$-0.02(-3.80%)

Fusen Pharmaceutical Company Limited (1652.HK) Company Profile & Overview

Explore Fusen Pharmaceutical Company Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Fusen Pharmaceutical Company Limited (1652.HK) Company Profile & Overview

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOZhiming Cao

Contact Information

Urban Industrial Zone, Nanyang

Company Facts

1,131 Employees
IPO DateJul 11, 2018
CountryCN
Actively Trading

Frequently Asked Questions

;